Motilat

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Motilat

Quick Facts

Property Description
Active ingredient Domperidone (INN)
Form Film-coated tablets, Oral suspension, Suppositories
Pharmacological class Dopamine Antagonist, Prokinetic Agent
Common use Relief of nausea, vomiting, and feelings of fullness
Origin Synthetic organic compound

Motilat: Definition and Pharmacological Classification

Motilat is a brand-name medicinal product whose active ingredient is Domperidone, an international non-proprietary name (INN) for a compound classified as a dopamine antagonist and functionally defined as a prokinetic agent. The substance is a synthetic organic compound and is formulated as a single-ingredient product. Domperidone is distinguished by its peripheral action, selectively blocking dopamine receptors primarily outside the central nervous system (CNS) in the chemoreceptor trigger zone and the gastrointestinal tract.

This mechanism is clinically recognized for its targeted effect on the digestive tract, as the substance exhibits minimal penetration of the blood-brain barrier at standard therapeutic concentrations. This peripheral selectivity is a characteristic of its pharmacological profile. Motilat, as a specific brand, is generally available as a prescription or over-the-counter medicine depending on the local regulatory entities, and is focused on symptomatic relief for adults and adolescents.


What Forms of Domperidone Are Available?

The Domperidone base is incorporated into several common dosage forms that allow flexibility in the route of administration. The most frequent pharmaceutical preparations are film-coated tablets and an oral suspension, both intended for oral administration. The composition involves the active drug combined with the necessary pharmaceutical base/vehicle (e.g., solid excipients or an aqueous vehicle) to facilitate stable delivery. The medicine may also exist as rectal suppositories for an alternative administration route. Various forms of domperidone-containing medicines are authorized for the management of the symptoms of nausea and vomiting. The availability of both solid and liquid forms ensures efficient delivery when conditions like acute nausea might impede the oral administration of a tablet.


General Purpose of Motilat as a Prokinetic Agent

The core therapeutic purpose of Motilat is the symptomatic relief of distress linked to disordered gastrointestinal motility, referring to the uncoordinated or slow muscle contractions of the upper digestive system. As a prokinetic agent, its function is to increase the tone and regularity of contractions, thereby promoting improved gastric emptying. This action is used in managing conditions where delayed stomach emptying contributes to discomfort. This generally helps to alleviate symptoms such as persistent nausea, episodes of vomiting, and feelings of abnormal epigastric fullness or abdominal distension after eating.

Regulatory References

  1. EMA Safety Review on Domperidone

What side effects are possible with Motilat?

Possible Side Effects and Safety Information

The safety profile of Motilat (Domperidone) is structured around official regulatory classifications, detailing adverse reactions by frequency and the body system affected.

Documented Adverse Reactions

Side effects are officially classified in regulatory documents according to their frequency, which typically includes Uncommon (occurring in fewer than 1 in 100 patients) and Very Rare (occurring in fewer than 1 in 10,000 patients). Uncommon effects include dry mouth, headache, anxiety, somnolence (drowsiness), and rash. These effects are grouped into system-organ classes such as Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Safety Considerations

The most serious documented safety concern relates to Cardiac Disorders. The official label highlights the risk of serious ventricular arrhythmias, including QTc prolongation and Torsade de Pointes, which can lead to sudden cardiac death. Other serious documented reactions include anaphylactic reactions (severe allergic reactions) and extrapyramidal disorders (involuntary movements), with the latter reported to be more frequent in infants and young children.

Regulatory Safety Patterns and Restrictions

Official regulatory documents enforce strict use limitations based on patient status and exposure. The risk of serious cardiac events is documented to be higher with daily oral doses exceeding 30 mg and in older patients (over 60 years). Motilat is formally contraindicated in individuals with a pre-existing prolonged QTc interval, certain electrolyte disturbances (such as hypokalaemia), underlying cardiac diseases, moderate to severe hepatic impairment, and when used concurrently with specific QTc-prolonging medicines or potent CYP3A4 inhibitors. These restrictions define the specific population for whom the medicine should not be used, based strictly on regulatory safety data.

Overdose and Emergency Response

The official regulatory profile for Motilat (Domperidone) details specific manifestations and actions required in the event of an overdose. Overdose primarily affects the Central Nervous System (CNS), presenting as sleepiness, disorientation, and confusion. Officially documented clinical signs include movement disturbances, specifically uncontrolled movements (extrapyramidal signs), such as unusual eye movements, movements of the tongue, and an abnormal posture like a twisted neck. These movement disturbances are officially noted to be more likely to occur in children.

The severe risk profile is concentrated on the Cardiovascular System. Regulator-documented outcomes include the potential for QT interval prolongation and serious ventricular arrhythmias, culminating in the risk of sudden cardiac death or seizure.

Immediate medical attention must be sought straight away upon suspected overdose. Urgent medical help is required if a seizure or fit or a fast or irregular heartbeat is experienced. Management is confined to standard symptomatic treatment, and regulatory bodies explicitly mandate that ECG monitoring be undertaken due to the serious, dose-related risk of cardiac effects.

Therapeutic Uses of Motilat

What Motilat treats: main uses and benefits

Motilat is a gastroprokinetic medication used to manage various digestive motility disorders. Its primary function is to facilitate the movement of food through the digestive tract by enhancing the coordination and strength of muscular contractions in the esophagus, stomach, and intestines.

Primary Uses

Motilat is primarily indicated for the relief of symptoms associated with delayed gastric emptying and gastroesophageal reflux. It is commonly used to treat:

  • Gastroparesis: A condition where the stomach takes too long to empty its contents. This can be caused by diabetes, post-surgical complications, or idiopathic factors. Symptoms include nausea, vomiting, early satiety (feeling full quickly), and abdominal bloating.
  • Gastroesophageal Reflux Disease (GERD): By increasing the pressure of the lower esophageal sphincter and improving gastric emptying, the medication helps prevent stomach acid and contents from flowing back into the esophagus, thereby reducing heartburn and regurgitation.
  • Functional Dyspepsia: This involves persistent or recurring pain or discomfort in the upper abdomen that does not have an obvious structural cause. Motilat helps alleviate the associated bloating, fullness, and discomfort.

Benefits and Mechanism of Action

The therapeutic benefits of Motilat stem from its ability to act as a selective dopamine antagonist. By blocking dopamine receptors in the gastrointestinal tract, the medication prevents the inhibitory effect of dopamine on muscle contractions.

Key benefits include:

  • Improved Gastric Emptying: It shortens the time food spends in the stomach, which reduces the pressure that causes reflux and nausea.
  • Enhanced Peristalsis: It promotes the rhythmic, wave-like contractions of the digestive tract, ensuring more efficient transit of material through the gut.
  • Symptom Relief: Most patients experience a significant reduction in chronic digestive discomfort, particularly the sensation of heaviness after meals and chronic nausea related to slow digestion.

Therapeutic Goals

The goal of treatment with Motilat is to restore a more natural rhythm to the digestive process. By improving the speed and coordination of the upper gastrointestinal tract, it helps stabilize digestion and improves the overall nutritional intake and comfort of individuals suffering from motility-related disorders.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Motilat?

Motilat (Domperidone) has strict population eligibility rules established by regulatory bodies primarily due to the risk of serious cardiac effects. Use is authorized for adults and adolescents 12 years of age or older who weigh 35 kg or more. The medicine is generally not licensed for children younger than 12 years of age.


Contraindicated Populations (Must Not Use)

  • Patients with moderate or severe hepatic (liver) impairment.
  • Patients with a prolonged QTc interval or underlying cardiac diseases (e.g., congestive heart failure).
  • Patients with significant electrolyte disturbances (e.g., hypokalaemia).
  • Conditions where stimulating gut movement is dangerous, such as gastro-intestinal haemorrhage or obstruction.
  • Patients co-administering with QT-prolonging drugs or certain potent CYP3A4 inhibitors.

Restricted or Conditional Use

  • Patients over 60 years of age require caution, as a higher risk of serious ventricular arrhythmias has been observed in this group.
  • Patients with severe renal impairment require a reduction in the dosing frequency.
  • Use during pregnancy and lactation is generally conditional and requires a physician to weigh the anticipated therapeutic benefit against potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Substances

Co-administration with Potent CYP3A4 Inhibitors is formally prohibited because these agents significantly inhibit the primary metabolic pathway of the drug. This inhibition leads to a substantial increase in domperidone plasma concentrations and systemic exposure. This prohibition includes potent inhibitors such as Azole Antifungals (e.g., Ketoconazole, Itraconazole) and certain Macrolide Antibiotics (e.g., Clarithromycin). Similarly, concurrent use with any QTc Prolonging Medicinal Products is contraindicated due to the documented risk of an additive pharmacodynamic effect on cardiac electrical activity, heightening the risk of serious ventricular arrhythmias. This restriction applies to various anti-arrhythmics and antipsychotics. The consumption of Grapefruit Juice is also formally contraindicated as it acts as a potent CYP3A4 inhibitor, increasing exposure.

Interaction-Related Restrictions and Cautions

The drug’s metabolism is primarily mediated by the CYP3A4 enzyme, and it is also documented as a substrate of the P-glycoprotein (P-gp) efflux transporter. The co-administration of Moderate CYP3A4 Inhibitors is generally not recommended by regulatory sources, as these substances also increase domperidone exposure. Caution is advised when co-administering with medicines that may induce bradycardia or hypokalaemia, as these conditions increase the pro-arrhythmic risk. Official data also reports that domperidone co-administration results in an increase in Levodopa plasma concentration.

Population-Specific Constraints

Motilat is formally contraindicated in patients with Moderate or Severe Hepatic Impairment due to prolonged elimination. For patients with Severe Renal Impairment, the prolonged elimination half-life requires that the dosing frequency should be reduced. The risk of serious heart rhythm disorders related to interactions has been observed to be higher in patients over 60 years old.

Mechanism of Action

The molecule functions as an antagonist at the Dopamine mathbfD2 receptors, primarily located outside the central nervous system (CNS) in the mathbfChemoreceptor mathbfTrigger mathbfZone (CTZ) and the upper mathbfgastrointestinal mathbftract. This selective, peripheral mathbfantagonism inhibits the mathbfemetic mathbfsignaling mathbfpathway.

In the gut, D2 receptor blockade removes dopamine's natural inhibitory influence on the mathbfmyenteric mathbfplexus's nerve cells. This physiological adjustment leads to an mathbfincrease mathbfin mathbfacetylcholine mathbfrelease, which is the primary chemical signal for muscle contraction. The resultant enhanced mathbfperistalsis increases mathbfLower mathbfEsophageal mathbfSphincter mathbfpressure and mathbfaccelerates mathbfgastric mathbftransit.

The drug's prokinetic mechanism is fundamentally dependent on an intact mathbfcholinergic mathbfpathway within the gut wall, meaning its function is mathbffunctionally mathbfconstrained by mathbfanticholinergic mathbfactivity. Furthermore, its biological targets are specific to mathbfD2 mathbfreceptors, limiting the mathbfD2 mathbfantagonism effect in pathways that are primarily mediated by mathbfnon-mathbfdopaminergic mathbfsignals.

Dosage and Administration Information

How to Use Motilat

The administration of Motilat (Domperidone) follows specific parameters that define the proper route, dosage limits, and duration of use. The medication is used at the lowest possible dose for the shortest duration necessary.


Official Administration Guidelines

Usage Parameter Instruction
Route of Administration The medicine is administered via the oral route (tablets, suspension) or the rectal route (suppositories, where authorized).
Standard Oral Dosing The maximum recommended daily oral dose for adults (12 years or older, weighing at least 35 kg) is 30 mg, divided into up to three 10 mg administrations per day.
Timing Relative to Meals Oral formulations should be taken before meals (e.g., 15 to 30 minutes prior), as food intake delays the drug's absorption.
Course Duration The maximum treatment duration for acute symptoms should generally not exceed one week (7 days).

Population-Specific and Procedural Rules

  • Pediatric Dosing: For children weighing less than 35 kg, tablets and suppositories are unsuitable. The dose for the oral suspension is calculated based on body weight (0.25 mg/kg, up to three times daily).
  • Renal Impairment: In cases of severe kidney impairment, the drug's elimination is prolonged, requiring the dosing frequency to be reduced (e.g., to once or twice daily).
  • Missed Dose Protocol: If a scheduled dose is missed, it should be omitted, and the patient should resume the regular dosing schedule; the dose should not be doubled to compensate.
  • Tablet Handling: Film-coated tablets must be swallowed whole with water and must not be crushed or chewed.

These instructions define an administration protocol, limiting both the daily intake (30 mg maximum) and the overall duration of use to ensure the drug is administered under controlled conditions.

Recent Clinical Evidence

Evidence for Acute Nausea and Vomiting Symptoms

Research exploring how symptoms change over time has focused on the use of Motilat for episodic or acute changes in physical discomfort related to nausea and vomiting. The clinical evaluation for this indication was conducted using short-term Randomized Controlled Trials (RCTs) in adult populations. These studies were designed to monitor changes by comparing the substance to an inactive substance (placebo).

Studies were designed to assess whether changes in patient-reported outcomes related to physical discomfort were observed when compared to a placebo. Research highlights changes measured during the study period, focusing on patient-reported outcomes describing perceived discomfort. Regulatory bodies have analyzed these outcomes, contributing to the context of the available evidence.

Evidence for Chronic Gastrointestinal Conditions

The evidence base for using Motilat in conditions marked by functional limitations, such as gastroparesis and functional dyspepsia, is structured differently. Research for these applications has involved a mix of systematic reviews, older clinical trials, and observational settings evaluating daily-life functioning.

Research on Gastroparesis Symptoms

Studies exploring short-term symptom changes in gastroparesis was evaluated in adult populations with documented delayed gastric emptying. Researchers monitored outcomes related to physical discomfort and objective measures related to stomach function. Findings were mixed across studies, and some observational data describe patterns of change in symptom scores within the monitored groups. Data are still emerging for this application, and certainty remains low due to methodological limitations.

Evidence in Specific Patient Groups and Research Gaps

Motilat was observed in trials that studied adults and adolescents weighing 35 kg or more. The data for younger children (under 12 or weighing less than 35 kg) remain insufficient. Systematic reviews suggest that reliable evidence of outcomes in these younger age groups is limited, and findings were inconclusive when compared to placebo.

The evidence highlights what is known—and what is still uncertain. Evidence is limited for the long-term outcomes related to both chronic conditions and for sustained use, as follow-up durations were limited in the key efficacy trials. The current evidence structure highlights that results apply only to the populations studied.

Key Studies & References

  1. PRODUCT MONOGRAPH: Domperidone Tablets, Modifier of Upper Gastrointestinal Motility (Health Canada Product Monograph Example)
  2. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis (Systematic Review)
  3. Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children (Pediatric RCT)

Frequently Asked Questions (FAQ)

Common questions about Motilat (FAQ)


Q: How quickly does Motilat (Domperidone) start working?

Official product information indicates that the active ingredient, domperidone, is rapidly absorbed after being taken by mouth. In people who have fasted (taken the medicine on an empty stomach), the substance typically reaches its highest level in the bloodstream in about 30 to 60 minutes. This absorption profile is the basis for its authorized use.


Q: How long does the effect of a Motilat (Domperidone) dose last?

The length of time the drug remains in the system is described by its plasma half-life, which is the time it takes for half of the substance to be eliminated by the body. For Motilat, the half-life is typically reported to be 7 to 9 hours after a single oral dose in healthy individuals. This biological duration is one factor considered when establishing official dosing guidelines.


Q: Does Motilat (Domperidone) affect my ability to drive or operate machinery?

The official product information for Motilat advises caution. Because the medication can sometimes cause side effects like dizziness and somnolence (drowsiness), official documents contain a warning against driving or operating machinery if these effects occur. Patients are advised to monitor their response to the medication before engaging in activities that require alertness.


Q: What should I do if I accidentally take too much Motilat (Domperidone)?

Taking more than the prescribed amount is considered an overdose and requires immediate attention. Symptoms of an overdose may include confusion, agitation, drowsiness, disorientation, and extrapyramidal reactions (involuntary muscle movements). In the event of a suspected overdose, the protocol is to seek immediate emergency medical assistance.


Q: Will Motilat (Domperidone) affect my lab test results?

Official reports indicate that the medication may affect the results of certain laboratory tests. Very rare side effects documented in the safety profile include abnormal liver function test results and an increase in blood prolactin levels. This effect is documented in the safety profile of the drug.


Q: Does Motilat (Domperidone) contain any gluten or lactose?

According to the official list of non-active ingredients (excipients), the film-coated tablets contain lactose. Because the tablets contain lactose, regulatory documents note that they may be inappropriate for patients with conditions such as lactose intolerance or related issues. The official product information does not specify the presence of gluten.


Q: Can I take Motilat (Domperidone) with herbal supplements or vitamins?

The official drug label focuses primarily on interactions with prescription medicines that affect how Motilat is processed by the body. While specific information on every herbal product or vitamin is generally not available in regulatory documents, regulatory documents emphasize the importance of communicating with a healthcare provider about all products being taken, including herbal remedies and nutritional supplements, due to the potential for interactions.


Q: Does taking Motilat (Domperidone) cause weight gain or weight loss?

Weight changes are not listed as a common or defined adverse reaction in regulatory documents for Motilat. However, official safety listings sometimes include changes in appetite, which can be related to shifts in body weight. If changes in body weight are a concern, consultation with a healthcare provider is generally recommended.


Q: Does Motilat (Domperidone) affect blood pressure?

While changes in blood pressure are not generally listed as a common adverse reaction, official warnings emphasize that Motilat is contraindicated (must not be used) in people with underlying cardiac diseases. This is due to a documented risk of serious ventricular arrhythmias, which are dangerous heart rhythm disorders.


Q: Can I drink alcohol while taking Motilat (Domperidone)?

Official drug labels generally warn that combining alcohol with medicines may lead to unpredictable interactions or increase the risk of certain side effects, especially those affecting the central nervous system. Official documents advise that patients should discuss the consumption of food, alcohol, and tobacco with their prescribing healthcare provider to review potential risks.

How should Motilat be stored and disposed of?

Storage and Disposal Requirements for Motilat

Motilat (domperidone) must be stored strictly according to the conditions defined in the official regulatory labeling to ensure product quality and safety.


Mandatory Storage Conditions

The medicine requires storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and must not exceed 30 C. The product must be kept out of sight and reach of children and stored in its original package with the container tightly closed to protect it from light and moisture.


Prohibited Storage and Disposal

It is explicitly required that Motilat must not be refrigerated or frozen. Unused or expired medicine must be discarded by following local/regional/national regulations for pharmaceutical waste and must not be emptied into household drains or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Motilat found in:

A-Z Index: